These interventions led to reduction in the expression of stemness and EMT markers, decreased migratory and invasive abilities of CRC cells, and heightened sensitivity to chemotherapy, suggesting a potential therapeutic approach to managing CRC by targeting CSCs through the modulation of DVL3 and the Wnt/β-catenin pathway [113]. This evidence concerns the gene DVL3 and colorectal carcinoma.